Audentes Therapeutics
Total Raised
$137.5MInvestors Count
15Deal Terms
5Funding, Valuation & Revenue
7 Fundings
Audentes Therapeutics has raised $137.5M over 7 rounds.
Audentes Therapeutics's latest funding round was a Acq - P2P for on December 2, 2019.
Audentes Therapeutics's valuation in July 2016 was $315.3M.
Audentes Therapeutics's latest post-money valuation is from December 2019.
Sign up for a free demo to see Audentes Therapeutics's valuations in December 2019 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
12/2/2019 | Acq - P2P | 3 | ||||
7/20/2016 | IPO | $315.3M | ||||
10/13/2015 | Series C | |||||
1/5/2015 | Incubator/Accelerator | |||||
12/2/2014 | Series B |
Date | 12/2/2019 | 7/20/2016 | 10/13/2015 | 1/5/2015 | 12/2/2014 |
|---|---|---|---|---|---|
Round | Acq - P2P | IPO | Series C | Incubator/Accelerator | Series B |
Amount | |||||
Investors | |||||
Valuation | $315.3M | ||||
Revenue | |||||
Sources | 3 |
Audentes Therapeutics Deal Terms
5 Deal Terms
Audentes Therapeutics's deal structure is available for 5 funding rounds, including their Acq - P2P from December 02, 2019.
Round | Acq - P2P | IPO | Series C | Series B | Series A |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acq - P2P | |||||||||||||||
IPO | |||||||||||||||
Series C | |||||||||||||||
Series B | |||||||||||||||
Series A |
Audentes Therapeutics Investors
15 Investors
Audentes Therapeutics has 15 investors. Astellas Pharma invested in Audentes Therapeutics's Acq - P2P funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
12/2/2019 | 12/2/2019 | 1 Acq - P2P | Corporation | Japan | ||
7/18/2013 | 10/13/2015 | 3 Series A, Series B (2014), Series C (2015) | Venture Capital | California | ||
7/18/2013 | 10/13/2015 | 3 Series A, Series B (2014), Series C (2015) | Venture Capital | New York | ||
Venture Capital | California | |||||
Venture Capital | California |
First funding | 12/2/2019 | 7/18/2013 | 7/18/2013 | ||
|---|---|---|---|---|---|
Last Funding | 12/2/2019 | 10/13/2015 | 10/13/2015 | ||
Investor | |||||
Rounds | 1 Acq - P2P | 3 Series A, Series B (2014), Series C (2015) | 3 Series A, Series B (2014), Series C (2015) | ||
Board Seats | |||||
Type | Corporation | Venture Capital | Venture Capital | Venture Capital | Venture Capital |
Location | Japan | California | New York | California | California |
Audentes Therapeutics Acquisitions
1 Acquisition
Audentes Therapeutics acquired 1 company. Their latest acquisition was Cardiogen Sciences on September 01, 2015.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
9/1/2015 | Seed / Angel | $0.53M | Acquired | 1 |
Date | 9/1/2015 |
|---|---|
Investment Stage | Seed / Angel |
Companies | |
Valuation | |
Total Funding | $0.53M |
Note | Acquired |
Sources | 1 |
Compare Audentes Therapeutics to Competitors
Orna Therapeutics is focused on advancing RNA therapeutics within the biotechnology sector. It specializes in developing a circular RNA technology platform and lipid nanoparticle delivery systems to enhance the therapeutic applications of circular RNA. Its innovations aim to contribute to the field of in vivo therapies for various diseases. It was founded in 2019 and is based in Watertown, Massachusetts.
Atomic AI is a biotechnology company at the intersection of artificial intelligence and structural biology, focusing on ribonucleic acid (RNA) drug discovery. The company develops a proprietary platform that utilizes deep learning to discover small molecules and medicines that target RNA. It was founded in 2021 and is based in South San Francisco, California.
GeneTether is a biotechnology company that works on targeted genome editing technologies. The company is developing a proprietary platform to improve the correction efficiency of these technologies. It was founded in 2018 and is based in San Lorenzo, California.
Evive Biotech operates as a biopharmaceutical company developing biological therapies for various diseases. The company specializes in drug candidates targeting oncology, inflammatory, and metabolic diseases using technology platforms. It serves the healthcare sector and aims to provide therapeutic offerings. It was founded in 2004 and is based in Beijing, China.
Baruch S. Blumberg Institute is a nonprofit organization that conducts translational research in the biotechnology sector, emphasizing virology and viral pathogenesis. The organization works on therapeutics for hepatitis B, liver cancer, and other viral diseases, as well as facilitating biotechnology through life science incubators. The Blumberg Institute also provides training and educational programs for the next generation of scientists. It was founded in 2003 and is based in Doylestown, Pennsylvania.
Bikam is a company that provides subscription services for periodicals and sells books and electronic products from various global publishers. The company offers access to scientific literature, academic texts, medical resources, technical publications, economic writings, antiquarian books, and electronic databases. It was founded in 1996 and is based in Sofia, Bulgaria.
Loading...